Connect Biopharma Holdings Ltd - ADR Stock

$1.11

14.42% day before yesterday

Nasdaq, Dec 27, 09:35 pm CET

ISIN

US2075231017

Symbol

CNTB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Connect Biopharma Holdings Ltd - ADR Stock price

$1.14

-15.86 93.29% 5Y

Nasdaq, Closing price Fri, Dec 27 2024

+0.17 17.53%

ISIN

US2075231017

Symbol

CNTB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$62.99m
Enterprise Value	$-46.85m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	0.60
P/B ratio (TTM) P/B ratio	0.57
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-89.13m
Free Cash Flow (TTM) Free Cash Flow	$-78.32m
EPS (TTM) EPS	$-1.59
P/E forward	negative
P/S forward	2.23
EV/Sales forward	negative
Short interest	0.18%

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Get Started for Free Today

Connect Biopharma Holdings Ltd - ADR Stock Analysis

Unlock Scores for Free

??

1 Analyst has issued a forecast Connect Biopharma Holdings Ltd - ADR:

1x Buy

100%

More details on Analyst Estimates Including Price Targets

1 Analyst has issued a forecast Connect Biopharma Holdings Ltd - ADR:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Connect Biopharma Holdings Ltd - ADR

Income Statement P&L | Balance Sheet | Cash Flow

TTM Annually

Jun '24		+/- %
Revenue	- -	- 100%
- Direct Costs	1.03 1.03	0% 0% -
Gross Profit	-1.03 -1.03	0% 0% -
- Selling and Administrative Expenses	-	-
- Research and Development Expense	71 71	0% 0% -
EBITDA	-88 -88	0% 0% -
- Depreciation and Amortization	1.03 1.03	0% 0% -
EBIT (Operating Income) EBIT	-89 -89	0% 0% -
Net Profit	-87 -87	0% 0% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Connect Biopharma Holdings Ltd - ADR Stock News

Neutral

GlobeNewsWire

●

2 months ago

Attovia Therapeutics Appoints Chief Financial Officer

Steven Chan, an accomplished finance leader, joins Attovia as Chief Financial Officer Steven Chan, an accomplished finance leader, joins Attovia as Chief Financial Officer

Positive

GuruFocus

●

3 months ago

CNTB Stock Surges Over 5% Amid Strong Financial Performance

Concordia Biotech (CNTB, Financial) saw a significant increase in its stock price, rising by 5.48%. The stock is currently priced at $1.49 per share with a trading volume of 16,435 shares and a turnover rate of 0.03%.

Neutral

GlobeNewsWire

●

4 months ago

Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update

SAN DIEGO, CA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma,” “Connect” or the “Company”), a U.S.-headquartered global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with inflammatory diseases, today reported financial results for the six months ended June 30, 2024 and provided a business update.

More Connect Biopharma Holdings Ltd - ADR News

Company Profile

Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma. The company was founded by Zheng Wei and Wu Bin Pan on November 23, 2015 and is headquartered in Taicang, China.

Head office	Cayman Islands
CEO	Barry Quart
Employees	81
Founded	2015
Website	www.connectbiopharm.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now